Argentina is a country characterized by a heterogeneous distribution of its population, its economic resources and, consequently, access to health services, which could affect the diagnosis and treatment of patients with myelodysplastic syndromes.
Based on the increasing complexity to arrive at the diagnosis, estimate the risk and indicate an adequate treatment, we have conducted a survey of twenty-three questions to evaluate patterns of clinical practice.
The questionnaire was distributed among 850 hematologists registered at the XXII ArgentineCongress of Hematology, and 195 (22.9%) were answered; 40.0% report that < 75% of their patients access the karyotype, bone marrow histology and flow cytometry.
This access decreases significantly due to low health coverage (OR 6.3), in the adult population (OR 3.8), when the cytogenetic study is derived (OR 3.2) and outside the metropolitan area of Buenos Aires (OR 2.4). The respondents avoid oncological terminologies (77.0%) when introducing the diagnosis and use the international prediction system or its review (74.2%) to stage risk. However, they prioritize age when selecting treatment and pediatricians preferentially recommend the transplantation of hematopoietic precursors.
[Linking template=”default” type=”products” search=”SKT-110-480″ header=”2″ limit=”190″ start=”2″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]
Most of the haematologists have prescribed the recommended treatments, whose suspensions were related to lack of response (62.7%), with reduced participation in clinical trials (8.9%). Therefore, they report heterogeneity in the access to complementary diagnostic tools with differences at the time of indicating a treatment, depending on the age of their patients without apparent limitations in their prescription.